Table 5.

Calculation of utility (N=207).

Disease stagea and assessment		Spain (N=63)						The Netherlands (N=66)						Taiwan (N=78)
		Do CHANGEb 2 (N=27)		TAUc (N=36)		P valued		Do CHANGE 2 (N=29)		TAU (N=37)		P valued			Do CHANGE 2 (N=36)		TAU (N=42)		P valued
Baseline disease stage
	M0e		0.896		0.869		.74		0.854		0.936		.40			0.875		0.638		.01
	M3f		0.900		0.950		.49		0.931		0.904		.83			0.911		0.847		.59
	Δg		0.004		0.081				0.077		−0.032					0.036		0.209
Progressive disease stage 1
	M0		0.871		0.719		—h		0.861		0.807		—			0.726		1		—
	M3		0.853		0.898		.57		0.861		0.904		—			0.726		1		.19
	Δ		−0.018		0.179				0		0.097					0		0
Progressive disease stage 2
	M0		0.912		0.875		.49		0.896		0.821		.23			0.877		0.895		.75
	M3		0.938		0.853		.07		0.886		0.825		.42			0.841		0.883		.56
	Δ		0.026		−0.022				−0.010		0.004					−0.036		−0.012
Progressive disease stage 3
	M0		0.964		0.889		.09		0.805		0.843		.42			0.832		0.870		.62
	M3		0.944		0.866		.21		0.852		0.872		.64			0.766		0.838		.32
	Δ		−0.020		−0.023				0.047		0.029					−0.066		−0.032

^aBaseline disease stage: systolic blood pressure (SBP) <120 mmHg and diastolic blood pressure (DBP) <80 mmHg; Progressive disease stage 1: SBP 120-129 mmHg and DBP <80 mmHg; Progressive disease stage 2: SBP 130-139 mmHg or DBP 80-89 mmHg; Progressive disease stage 3: SBP ≥140 mmHg or DBP ≥90 mmHg.

^bDo CHANGE: Do Cardiac Health: Advanced New Generation Ecosystem.

^cTAU: treatment as usual.

^dA P value <.05 is considered significant.

^eM0: baseline assessment.

^fM3: assessment at 3 months.

^gΔ: M3 – M0.

^hNot enough data to calculate a P value.